Arrowhead Closes Underwritten Offering with Gross Proceeds of $120 Million

[Business Wire] – Arrowhead Research Corporation , a biopharmaceutical company developing targeted RNAi therapeutics, today announced that on February 24, 2014 it closed the previously announced underwritten offering of 6,325,000 shares of common stock, more

View todays social media effects on ARWR

View the latest stocks trending across Twitter. Click to view dashboard

See who Arrowhead is hiring next, click here to view